The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition.
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it will participate in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings planned as it explores potential licensing, strategic partnerships, and M&A opportunities.
The Company’s lead candidate, Ketamir-2, a next-generation oral ketamine analog, is currently undergoing a Phase 1 clinical trial. With the second dosing cohort completed, the Company is now preparing to initiate the third cohort. Building on this momentum, MIRA anticipates initiating a Phase IIa study in neuropathic pain before the end of the year, advancing the development of what the Company believes could be a safe, effective non-opioid alternative for chronic pain management.
In addition, MIRA is advancing a series of preclinical studies with Ketamir-2, including models evaluating its potential in PTSD, as well as a topical formulation aimed at treating localized inflammatory pain. The Company is also finalizing regulatory filings related to its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”), with submission to the U.S. Securities and Exchange Commission (SEC) expected in the coming weeks. SKNY-1, SKNY’s primary pharmaceutical candidate, is being developed as an oral therapeutic targeting smoking cessation and obesity, with activity at CB1, CB2, and MAO-B receptors.
“Our pipeline is advancing on all fronts, and we are focused on turning this scientific momentum into long-term value for patients and shareholders,” said Erez Aminov, Chief Executive Officer of MIRA. “As we move closer to initiating Phase IIa and completing the SKNY transaction, we’re actively exploring strategic opportunities to accelerate growth, including licensing and partnerships-especially in areas like chronic pain where non-opioid alternatives like Ketamir-2 are urgently needed.”
Dr. Angel, Chief Scientific Advisor at MIRA, added: “We believe Ketamir-2 is paving the way for a new class of non-opioid therapies. The science is compelling, and the progress we have made is truly exciting. I look forward to sharing the depth of our work and the promising data we’ve generated with potential partners and investors.”
Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market
Initial production has commenced with six flavor options
Expanded pre-launch consumer testing planned for Q2 2025
Aspire to launch BUZZ BOMB™ at two major upcoming fitness conventions
Marketing plan focused on cost-effective multi-channel digital strategy targeting primary influencers, direct response sales and traditional retail sales channels
Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030
HUMACO, PUERTO RICO and NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced the brand name BUZZ BOMB™ and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB™ features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential.
Aspire has commenced initial production of BUZZ BOMB™, its single serving pre-workout caffeine supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery technology.The pre-workout formula is conveniently packaged in a single serving packet for easy on-the-go use. Consumers will have a choice of six BUZZ BOMB™ flavors, including Tropical Fruit, Mixed Berry, Watermelon, Lemon Lime, Peach Mango, and Mocha Coffee.
Fitness Convention Booth and Sponsor Events for BUZZ BOMB™ Launch
The Company expects to begin expanded pre-launch consumer testing of this supplement product during the second quarter of 2025. In August, the Company will have a booth and be an event sponsor at two of the largest fitness conferences in the nation where over 50,000 people interested in health, fitness, optimization, nutrition, and overall wellbeing will be able to taste, sample, and experience the BUZZ BOMB™ pre-workout supplement.
“The introduction of Aspire’s caffeine-based “Buzz Bomb™” Sublingual Pre-Workout energy supplement has the ideal unique characteristics to disrupt the fast-growing, multi-billion-dollar Sports Nutrition and Fitness market,” said Kraig Higginson, Chief Executive Officer of Aspire. “We are excited about the early feedback from fitness trainers and athletes-who love how clean and simple our product is–and we look forward to the implementation of our phased marketing plan as we prepare for our market launch in the early third quarter. Initial production, performed by Desert Stream, a leading private label manufacturer in the health and wellness industry, has proceeded as planned and we expect to have ample product available for consumer testing and launch.
While we are initially focused on the fitness pre-workout market, we believe the product also has tremendous broad market appeal in the Cognitive Focus and Energy Boost markets for professionals seeking a safe, healthy way to meet energy demands at work. We believe it may also appeal to a growing Health and Nutrition market as a weight loss enhancement, and as a coffee alternative, providing the taste, energy, and cognitive boost of coffee, while on the go, without the adverse effects of disrupting the gut micro biome and the liver, that is associated with long term coffee consumption.”
Higginson added, “As part of our commercial and revenue strategy, BUZZ BOMB™, is expected to provide Aspire with the opportunity for rapid, cost-effective market entry, and early revenue and cash flow while we complete our FDA clinical trials and application process for our high-dose aspirin product.”
BUZZ BOMB™: Disruptive Characteristics
The Pre-Workout supplement market segment is flooded with many options for energy boosting and hydration products. Many, if not most, of these products today are based on a powdered “mix + water” combination that take 20-30 minutes to digest and begin to provide performance benefits. This disadvantage complicates use, response management, caffeine control, and effectiveness. In contrast, Buzz Bomb™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed.
Market research shows that immediacy, ease of use and time management (take as needed, when needed) ranks highest in consumer preferences. Buzz Bomb™ offers potentially disruptive benefits and product characteristics that is expected to drive market penetration with significant differentiation, leading to rapid customer conversion, acquisition, and brand identity in this market.
Aspire’s sublingual nano technology is designed to deliver caffeine directly to the blood stream, bringing its unique disruptive benefits to the Pre-Workout market. These unique benefits provide significant product differentiation from powder mix beverage products that currently dominate the market segment.
BUZZ BOMB™ Disruptive Features:
Speed – works nearly immediately vs. 20-30 minutes
Convenience – easy to use small packets vs. mix beverages
Energy management – use as needed, when needed to manage energy
Single Safe Ingredients – well known benefits and use of caffeine
Low manufacturing & packaging costs – competitive pricing with high margin potential
According to Research and Market Reports recent report, “The global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030.”
Growth Drivers
Rising fitness culture and gym memberships
Consumer focus on performance and recovery
Expanding demographics (women, Gen Z, casual exercisers)
Growth of RTD (“Ready To Drink”- no mixing) formats & natural formulations
Digital fitness and influencer-led marketing
About the Aspire Targeted Oral Delivery Platform
Aspire’s technology delivers a soluble, fast acting granular or powder formulation which has been developed by using our patent-pending methodology, and “trade secret” process. The technology’s new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of supplements and other substances. The benefits of “rapid absorption” are to provide rapid impact in more precise quantities.
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
AUSTIN, TX / ACCESS Newswire / May 28, 2025 / Volcon ePowersports (Nasdaq:VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, is pleased to announce the launch of a new floor plan financing and retail financing program provided by Dealer Direct Financial, a department of First Community Bank. This initiative will enable Volcon’s network of dealers to finance their inventory purchases, providing them with enhanced access to the Company’s groundbreaking electric off-road vehicles.
The floor plan will provide flexible financial solutions designed to support inventory acquisition and drive sales of Volcon’s cutting-edge products. By facilitating dealer access to affordable financing, Volcon aims to expand its market presence and ensure that customers nationwide can experience the next generation of off-road adventure with the Company’s electric vehicles.
“We are excited to offer this floor plan program to our dealer network, which will empower them to grow their businesses while helping accelerate the adoption of our all-electric off-road vehicles,” said John Kim, CEO of Volcon. “This program reflects our commitment to strengthening dealer relationships and furthering our mission to revolutionize the powersports industry with sustainable, high-performance electric vehicles.”
The new floor plan program is a significant step in Volcon’s strategy to scale its operations and support its growing network of dealers as they meet increasing demand for Volcon’s innovative electric powersports offerings.
“We’re proud to partner with Volcon in supporting their innovative approach to the powersports market,” said Steve Wilcoxon, president of Dealer Direct Financial. “Our floor plan program is designed to give dealers the flexibility and access they need to meet customer demand and grow their businesses. By offering tailored financing solutions, we’re helping bring Volcon’s electric off-road vehicles to more showrooms-and more riders-across the country.”
About Volcon
Based in the Austin, Texas area, Volcon was founded as the first all-electric power sports company producing high-quality and sustainable electric vehicles for the outdoor community. Volcon electric vehicles are the future of off-roading, not only because of their environmental benefits but also because of their near-silent operation, which allows for a more immersive outdoor experience.
Volcon’s vehicle roadmap includes both motorcycles and UTVs. Its first product, the innovative Grunt, began shipping to customers in late 2021 and combines a fat-tired physique with high-torque electric power and a near-silent drive train. The Volcon Grunt EVO, an evolution of the original Grunt with a belt drive, an improved suspension, and seat, began shipping to customers in October 2023. The Brat is Volcon’s first foray into the wildly popular eBike market for both on-road and off-road riding and is currently being delivered to dealers across North America. In 2024, Volcon entered the rapidly expanding LUV and UTV market and shipped its first production MN1 unit in October 2024. The new MN1 and HF1 products empower the driver to explore the outdoors in a new and unique way that gas-powered units cannot. They offer the same thrilling performance of a standard LUV / UTV without the noise (or pollution), allowing the driver to explore the outdoors with all their senses.
For more information on Volcon or to learn more about its complete eBike, motorcycle and side-by-side line-up, visit: www.volcon.com
For more information about First Community Bank’s Dealer Direct program, call 870-376-7123 or visit https://dealerdirectfinancial.com.
Forward-Looking Statements
Some of the statements in this release referenced in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether floor plan program will increase dealer purchases of Volcon products. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.
About Dealer Direct Financial
Dealer Direct Financial is a department of First Community Bank, headquartered in Batesville, Arkansas. The program was established in 2005 in response to a need among local manufacturers for floor plan and retail financing solutions. Since its inception, Dealer Direct Financial has experienced significant growth and now services thousands of dealers nationwide. The program offers specialized financing for manufacturers, including floor plans and retail installment loans for tractors (up to 75hp), trailers, boats, powersports, motorcycles, lawn equipment, and farm equipment.
About First Community Bank
First Community Bank, which is locally owned and managed, opened August 4, 1997, in Batesville, Arkansas, and currently operates in 34 locations across Arkansas and Missouri. First Community Bank employs 600 professional bankers, and reports assets of $3.09 billion as of March 31, 2025.
Strongway Gym Supplies continues to support home gym owners across the UK by releasing user-friendly and high-performing training equipment that suits various fitness needs. One of their most recent additions is the Cable Crossover Machine with Weights, which combines space-efficient design with exceptional workout versatility. Unlike wall-mounted units, this model stands freely, making it easier to reposition within a home gym without needing permanent fixtures. The integrated weight stacks on either side offer a broad range of resistance settings, enabling users of all levels to adjust their workouts quickly without fumbling with weight plates. Dual pulleys allow for isolated muscle engagement and functional movements such as standing cable rows, chest flyes, wood chops, and core twists, key exercises often overlooked in traditional free-weight setups.
This freestanding machine not only brings professional-level training to domestic settings but also eliminates many of the challenges associated with wall mounting. It’s especially useful for households where wall space is limited, or for renters who need portable solutions that don’t require permanent installation. Its build quality and stability ensure a smooth, safe cable motion throughout, giving users a reliable experience during every workout session. The machine is also designed to accommodate a wide range of user heights and fitness goals, making it suitable for individual or family use. Interested customers can explore the full product listing here: https://strongway.co.uk/products/strongway-cable-crossover-with-weights.
For individuals working with even tighter spaces, Strongway also offers a Wall-Mounted Cable Crossover alternative. This variation provides many of the same movement possibilities, such as lat pushdowns, face pulls, and cable curls, while taking up less floor space. Ideal for garage gyms, compact spare rooms, or multipurpose areas, this model can be mounted securely onto a strong surface, turning any wall into a functional strength-training station. The height-adjustable pulleys allow users of different heights to customise their setup, and the compact profile makes it easier to plan around other gym equipment.
While it requires some installation effort, the wall-mounted option offers an excellent return on space efficiency and training variety. With the correct mounting surface and planning, users can achieve a gym-standard workout zone at home. Its robust construction and smooth operation ensure it can support regular use, whether for general fitness, sport-specific training, or rehabilitation. Those exploring more compact cable solutions can learn more by visiting: https://strongway.co.uk/products/strongway-wall-mounted-cable-crossover.
To further enhance the capabilities of both cable machines, an adjustable weight bench can be introduced into the training environment. Strongway’s range of foldable and adjustable benches supports incline, decline, and flat positions, making them ideal companions for cable-based exercises. By combining an adjustable bench with a cable crossover unit, users can access an entirely new range of movements such as seated chest flyes, incline cable presses, cable pullovers, and single-arm rows. This integration not only adds variety to workout routines but also allows for more effective targeting of specific muscle groups in a controlled, supported manner.
The foldable nature of Strongway’s adjustable benches means they can be stored vertically or under other equipment when not in use, an essential feature for those working with restricted space. Their solid build and supportive padding ensure comfort and safety, even during longer or more intense sessions. Each bench is designed with ease of adjustment and long-term durability, giving fitness fans full control over positioning and comfort. For a closer look at Strongway’s adjustable bench collection, visit: https://strongway.co.uk/collections/adjustable-bench.
Together, these three products create a well-rounded home gym experience. While cable machines are ideal for isolating muscles and performing functional training movements, the adjustable bench opens the door to expanded strength and hypertrophy options. Whether you’re building a gym from scratch or adding to an existing setup, these additions help create a balanced training space that caters to beginners and more experienced lifters alike.
As interest in home-based training continues to grow in the UK, Strongway Gym Supplies remains committed to providing affordable, space-conscious, and effective equipment for all levels of home gym users. Their product range is designed with practicality, performance, and durability, backed by reliable delivery and customer support.
Users interested in building or upgrading their home gym setups can find more information and place orders by visiting the links provided above.
TAMPA, FLORIDA / ACCESS Newswire / May 28, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced key additions to its executive leadership team and Board of Directors. These strategic appointments reflect the Company’s commitment to executing on its growth strategy, enhancing operational scale, and delivering long-term shareholder value.
Key Leadership Appointments
Wellgistics has appointed a diverse and deeply experienced group of executives to drive execution across the Company’s operations:
Tony Madsen, Chief Operating Officer (COO) – A seasoned executive with over a decade of regulatory compliance, cybersecurity, and healthcare operations scaling experience. Mr. Madsen will oversee execution across Wellgistics’ platform and ensure cross-functional alignment and operational excellence. Since 2020, he served as Managing Partner at Nomad Capital, an investment firm dedicated to reshaping capital structures and fine-tuning operational efficiencies. For the six years prior, he was Director of Cybersecurity at Cingo Solutions, an SOC2-certified managed detection and response cybersecurity provider. He holds a degree in Economics from Brigham State University.
Shelley Bailey, Chief Revenue Officer (CRO) – A proven growth strategist, Ms. Bailey brings deep industry knowledge and leadership in scaling healthcare sales teams and revenue operations across multiple verticals. Most recently, she served as Chief Strategy Officer at Wellgistics, where she combined her specialty pharmacy, government affairs, and supply chain experience to create tailored employer solutions. For the three years prior, she was the Chair of the Oregon Prescription Drug Affordability Board, a branch of that state’s largest consumer protection and business regulatory agency. Between 2020 and 2025 she served as founder and CEO of Famlee Health, which provided clinical assessment, diagnosis and step-therapy treatment for fertility from home. For the seven years prior, Ms. Bailey was a Specialty Pharmacy Consultant to legislators, pharmaceutical, and healthcare companies with a focus on specialty pharmacy and 340B programs. Between 2000 and 2017 she was CEO and co-owner of Central Drugs Specialty Pharmacy in Oregon. She earned an MBA from Babson F.W. Olin Graduate School of Business.
Srini Kalla, Chief Information Officer (CIO) – Mr. Kalla will lead the modernization of Wellgistics’ digital and data infrastructure, driving the Company’s AI integration strategy, compliance frameworks, and platform interoperability. Prior to joining Wellgistics, he worked with Optum Workers’ Comp and Auto No-Fault, a Minnesota-based insurance company, where he first served as Executive Director and then Vice President IT. Previously, he was employed in Analyst-Security Operations and Specialist-Operations Support by Verizon Data Services. He holds MS and MIS degrees from the University of Florida.
Vasudev Patel, Product Owner – Mr. Patel will spearhead product development across the Company’s AI-driven prescription routing tools, pharmacy technology platforms, and digital patient engagement solutions. Prior to joining Wellgistics, Mr. Patel held the position of Agile Product Owner with Evernorth Health Services. From 2012 to 2022 he served as Senior Business Analyst at UnitedHealth Group. He previously held Business Analyst positions with both Express Scripts and Merrill Lynch/Bank of America. He holds an MBA, Finance, from Brain Wells University in London.
Ari Aichbhaumik, Senior Vice President of Supply Chain – Mr. Aichbhaumik brings a strong track record of optimizing pharmaceutical supply chain networks at scale, with expertise in distribution, logistics, and global procurement. Before joining Wellgistics, Ari held a number of pharmacy operations management positions including Senior Vice President with Bayvrio, VP, Pharmacy Practice and Specialty Solution at Eversana, and Director of Pharmacy Operations at WellDyne, Inc. He holds degrees in Pharmacy from Temple University and Pharmaceutical Economics from University of Florida, as well as an MS, Computer Information and Business Management from the University of Phoenix.
Kim Dresser, Director of Human Resources – Ms. Dresser will drive talent acquisition, culture transformation, and HR infrastructure as Wellgistics continues to scale nationally.
Most recently, Kim served as Human Resources Director for Leonard Buildings & Truck Accessories, a 150-store, 18-state manufacturer and distributor. Previously, she was Human Resources Manager for MVP Group International, one of the world’s largest manufacturers of private label scented candles. From 2016 through 2021 she served as Production Manager at World Wide Protective Products, a maker of custom hand and body protection products. She holds an Associate degree in Business Management from Surry Community college in North Carolina.
Board Appointment
Michael Peterson, Member, Board of Directors – A veteran public company executive and capital markets strategist bringing significant governance and financial experience, Mr. Peterson will help guide Wellgistics’ strategic expansion and shareholder engagement.
Since 2022 Michael has served as CEO, Director, and Founder of Lafayette Energy, a Utah based oil and gas exploration company. He also presently serves as Director with both the biopharma company, Ocean Biomedical, and with the energy exploration company, Indonesia Energy Corporation. Michael also served as Director and CEO with Trio Petroleum Corp and as Director with TRxADE Health, Inc. (Nasdaq: MEDS), a wholesale drug selling platform. He holds an MBA, Finance, from Brigham Young University Mariott School of Business.
“This is more than just leadership expansion-it’s the strategic assembly of a world-class team capable of executing on our national vision to fundamentally shift the way prescription drugs move across the supply chain in America,” commented Brian Norton, CEO of Wellgistics Health. “We’re not just optimizing logistics-we’re rebuilding the infrastructure of healthcare medicine delivery to create lasting value for employer groups, patients, pharmacies, and the entire healthcare ecosystem.”
About Wellgistics Health
Wellgistics Health, Inc. is a publicly traded healthcare infrastructure company redefining how medications move, are priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a nationwide network of over 6,000 independent pharmacies.
Wellgistics Health provides real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment solutions, while equipping pharmacies with integrated financial, clinical, and digital tools. Its end-to-end platform supports a broad range of therapeutic areas from specialty-lite to chronic maintenance medications by eliminating friction, accelerating reimbursements, and enabling direct, transparent connections between manufacturers, providers, pharmacies, and patients.
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health’s statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans, including without limitation its plan in connection with certain financings and cryptocurrencies and outlook and actions with respect to incurring future expenses. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, which are available for review at www.sec.gov.
Investor Relations Contact: Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Office: (646) 893-5835 Email: info@skylineccg.com
Made in the USA, Built to Perform: Ultra-High Molecular Weight Polyethylene Parts Designed for Durability, Customization, and Speed
SIOUX FALLS, SD / ACCESS Newswire / May 28, 2025 / Global Polymer Industries, a premier compression molder of Ultra-High Molecular Weight Polyethylene (UHMW-PE), is proud to announce its continued leadership as North America’s top provider of custom-molded UHMW-PE components. From forestry and food processing to wastewater, agriculture, and advanced OEM manufacturing, Global Polymer delivers high-performance net-shape parts engineered to outperform traditional materials in even the harshest environments.
UHMW-PE is a unique thermoplastic with a molecular weight between 3.1 and 10 million, resulting in exceptional wear resistance, impact strength, low friction, and chemical resistance. But what sets Global Polymer Industries apart is not just the material, it’s how they mold it.
“Our compression-molding capabilities allow us to produce net- or near-net-shape UHMW-PE components that eliminate the need for costly secondary machining,” said Jeff Hieb, Plant Manager for Global Polymer. “That means faster turnaround, lower overhead, and exact-fit parts tailored to each customer’s equipment needs.”
Built in America. Built for Reliability. With U.S.-based operations, Global Polymer helps manufacturing companies and OEMs reduce reliance on overseas suppliers and achieve shorter lead times. By partnering with Global Polymer, companies gain a competitive edge:
Superior Material Performance – UHMW-PE parts resist wear, abrasion, moisture, and chemicals better than many metals or standard plastics.
Faster Delivery – Located in South Dakota, Global Polymer can produce and ship custom parts in significantly less time than offshore competitors.
Custom Molding Expertise – Whether it’s sprockets for agriculture, wear liners for conveyors, or bushings for car wash systems, Global Polymer builds each part to spec and scale.
Why OEMs Are Switching to UHMW-PE from Global Polymer Many OEM engineers are discovering that UHMW-PE’s properties, combined with Global Polymer’s net-shape molding process, can replace more expensive, heavier, or high-maintenance materials like steel, rubber, or nylon.
Industries seeing the most benefit include:
Forestry: Custom bushings, sprockets, and log-handling components that last longer with less maintenance.
Water & Wastewater: Chemical- and abrasion-resistant parts like liners, seals, and auger bearings.
Distribution & Packaging: Wear strips, chain guides, and dock bumpers that enhance flow and reduce friction.
Transportation & Marine: Corrosion-resistant snowplow blades and dock protectors that perform in rugged environments.
OEM Manufacturing: Custom-molded, high-volume parts, like wear pads, chain guides, and bushings, delivered with consistency and precision.
Global Polymer’s facility is engineered for both large-scale production and specialty part runs. From high-volume replacement parts to custom components for new equipment, their team partners directly with procurement specialists, engineers, and supply chain managers to streamline sourcing and maximize ROI.
About Global Polymer Global Polymer is a North American leader in the compression molding of UHMW-PE components. With advanced manufacturing capabilities and an unwavering commitment to quality, the company specializes in custom-molded net-shape parts used across a wide range of industries. Built in the USA, Global Polymer helps OEMs reduce costs, improve part performance, and accelerate delivery-without compromising durability or precision.
TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / May 28, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF)(FSE:OGF) (“Organto” or “the Company”), is pleased to announce its financial results for the three months ended March 31, 2025. All amounts are expressed in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), except where specifically noted.
Hi-Lites
Sales of $13.6 million, an increase of 193.5% versus the prior year. Largest quarterly sales in the history of the Company and representing 66% of total fiscal 2024 sales.
Gross profit of $1.1 million, an increase of 298.1% versus the prior year. Largest quarterly gross profit dollars in the history of the Company.
Cash operating expenses of 6.8% of sales versus 10.5% in the prior year. Lowest cash operating expenses as a percentage of sales in the history of the Company.
Income from operations of $0.1 million versus a loss of $0.3 million in the prior year.
EBITDA(1) (Earnings before interest, taxes, depreciation and amortization) of $0.3 million, the first positive EBITDA quarter in the history of the Company.
“We’re very pleased with our first-quarter 2025 results, which we believe are a powerful reflection of the strong momentum building in our business. These results are the direct outcome of the extensive restructuring and strategic realignment we’ve executed over the past 18 months, laying a solid foundation for sustained growth, stability, and a clear path to profitability.
As our results reflect, we have made substantial progress: we’ve streamlined our product portfolio, re-energized our go-to-market strategies, and significantly reduced operating costs. The first quarter of 2025 delivered exceptional sales and margin growth, all on a leaner, more efficient cost base, resulting in our first-ever positive EBITDA quarter. With strong, ongoing momentum and a continued focus on achieving positive cash flow, we’re moving forward with confidence. Our recent successful private placement, shares-for-debt settlements, and the imminent conversion of our convertible debentures into equity only amplify our excitement about what’s ahead. We’re passionately committed to building a world-class company serving the fast-growing healthy foods market, and in doing so creating lasting value for our partners, customers, team, and shareholders”, commented Steve Bromley, Chair and Chief Executive Officer.
Fiscal 2025 First Quarter Results Overview
Sales of $13.6 million versus $4.6 million in the prior year, an increase of approximately 194%. Sales grew as new customers were added, while a number of existing customers increased their purchases. Q-1 sales represent the largest quarterly sales in the history of the Company and 66% of total fiscal 2024 sales.
Gross profit of $1.1 million or 8.2% of sales, versus $0.3 million or 6.0% of sales in the prior year, an increase of approximately 298% in gross profit dollars. Adjusted gross profit(1) was $1.1 million or 8.3% of sales when accounting for the impact of realized gains on derivatives, versus $0.2 million or 4.7% of sales in the prior year.
Cash operating expenses of $0.9 million or 6.8% of sales versus $0.5 million or 10.5% of sales in the prior year. Operating expenses have stabilized following the sales of three subsidiaries in Q-2 2024 and reflect the increased costs of operating that were previously borne by the sold subsidiaries. First quarter costs include approximately $20,000 in legal and listing fees related to re-listing activities.
Income from operations of $0.1 million versus a loss of $0.3 million in the prior year. Adjusted income from operations of $0.2 million in the first quarter, when adjusted for costs associated with re-listing and realized gains on derivatives.
Net loss for the period of $0.3 million after accounting for interest and accretion costs of $0.3 million and unrealized losses on derivative assets and liabilities of $0.2 million, versus a loss in the prior year of $1.5 million which includes discontinued operations.
EBITDA(1) of $0.3 million versus a loss in the prior year of $1.2 million
The Company’s filings, including Audited Financial Statements and accompanying Management’s Discussion and Analysis for the year ended December 31, 2024 at www.SEDARplus.ca or at the Company’s website at www.organto.com under the Investors tab.
Grant of Stock Options
The Company has also granted stock options (the “Options”) exercisable to acquire up to 1,400,000 common shares to directors, officers and employees of the Company at a price of $0.35 per common share, expiring on May 27, 2030. 775,000 of the Options granted will vest 25% immediately and 25% every six months thereafter; and 625,000 of the Options granted will vest 20% immediately and 20% on each anniversary thereafter.
The Options were granted pursuant to the Company’s stock option plan which was last approved by shareholders at the Annual Meeting of Shareholders on March 12, 2025.
ON BEHALF OF THE BOARD,
Steve Bromley Chair and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
For more information contact: Investor Relations info@organto.com John Rathwell, Senior Vice President, Corporate Development and Investor Relations 647 629 0018
The information presented herein refers to the non-IFRS financial measures of adjusted gross profit and EBITDA. We hedge currencies for certain product categories where either the supply or sales commitments are fixed in foreign currencies. The gains and losses from these hedging activities are combined with gross profit to determine adjusted gross profit. We also refer to EBITDA, which is Earnings before interest, taxes, depreciation and amortization. These two measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS. Non-IFRS financial measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS and are unlikely to be comparable to similar measures presented by other issuers. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures. The Company believes that securities analysts, investors and other interested parties frequently use non-IFRS financial measures in the evaluation of the Company. The Company’s management also uses non-IFRS financial measures to facilitate operating performance comparisons from period to period and to prepare annual operating budgets and forecasts.
ABOUT ORGANTO
Organto is an integrated provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-light business model to serve a growing socially responsible and health-conscious consumer around the globe. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.
FORWARD LOOKING STATEMENTS
This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that the impact of these restructuring efforts is a key driver of its first quarter results; Organto’s belief that the combination of financing and debt restructuring efforts combined with strong sales and margin growth on a streamlined cost base positions the Company for an exciting future; Organto’s belief that it remains focused on building a world class company focused on growing healthy foods markets with the gaol of building shareholder value; management’s beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.
SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the BIO International Convention, 2025, Boston, MA
Day & Date
Monday, June 16, 2025
Time
2:30 pm
Location
Room 153B, Boston Convention and Exhibition Center
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025.
NanoViricides’ Current Antiviral Drugs Pipeline
NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region.
NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. An estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs.
The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This is completely unlike existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins.
The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.
NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.
NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.
In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code-Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready.
Whether you work at a public pharmaceutical company, biotech startup, academia, non-profit organization, or government agency; or you work as a researcher, business development professional or investor, BIO is where you’ll make valuable connections and build relationships. Our proprietary BIO Partnering™ match-making platform-exclusive to the Premier Access registration package-allows you to find potential partners, schedule and accept meetings.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
El Cajon, CA – Carini Home Services, a licensed HVAC, plumbing, water heater, and electrical contractor headquartered in El Cajon, announced a significant service expansion to better serve residential clients across San Diego County. Effective immediately, the company’s full range of professional services will now be available to Del Mar, Chula Vista, Poway, Oceanside, La Mesa, and National City homeowners.
Carini Home Services has built a reputation for technical excellence and dependable service in the El Cajon area for over a decade. This latest expansion represents the company’s continued growth and commitment to meeting increased demand for reliable home service providers in coastal and inland communities. In addition to its core HVAC offerings, including air conditioning repair and installation, furnace services, and system diagnostics, Carini Home Services now brings its complete electrical expertise to homes countywide.
“More and more homeowners are looking for one trusted team to handle their entire home comfort system, from heating and cooling to hot water and now electrical safety and upgrades,” said Gabriel Carini, founder and owner. “Expanding our services and geographic coverage is how we deliver on that trust.”
Carini Home Services licensed electricians provide a full range of services, including panel upgrades, lighting installations, circuit repairs, and smart home system wiring. Whether modernizing older wiring in a coastal home or adding a dedicated circuit for an EV charger, the electrical team brings precision and safety to every project. Their work is compliant with California building codes and designed for long-term performance.
Technicians across all service lines hold certifications such as EPA 608 and NATE for HVAC and C-10 licensing for electrical services. The company’s cross-trained workforce performs load calculations, thermostat calibrations, water heater replacements, and complete system inspections to ensure every home runs efficiently and safely.
Customer demand, energy efficiency goals, and regional climate challenges influenced expanding into new service areas. From the high humidity and salt exposure of coastal Del Mar and Oceanside to the aging infrastructure in cities like Chula Vista and La Mesa, every location presents unique technical requirements. The technicians are trained to identify these conditions and tailor their solutions to suit each home.
Energy prices across California continue to rise, prompting the need for services that help residents save money while maintaining comfort and safety. The company now offers consultations on smart thermostats and high-efficiency systems that can be paired with remote monitoring. These energy-saving strategies are complemented by professional electrical assessments that ensure a home’s panel and circuits are equipped to handle modern demands, including solar integration and EV charging.
By expanding its service area and staff, Carini Home Services aims to reduce response times, especially during peak seasons when HVAC and plumbing issues can quickly escalate. The company’s service vehicles are fully stocked with quality replacement parts, diagnostic tools, and safety equipment, allowing most issues to be resolved on the first visit.
“Our goal has always been simple: deliver fast, respectful, and high-quality service that homeowners can count on,” said Gabriel Carini. “We’re proud to bring that same commitment to more neighborhoods across San Diego.”
The expanded reach benefits new and existing clients, especially those with multiple properties. Property managers and homeowners with secondary residences now have access to one provider for HVAC, plumbing, electrical, and water heater needs, simplifying maintenance and repairs across properties.
Carini Home Services is also investing in workforce development to support growth. The company is actively hiring licensed HVAC technicians, plumbers, electricians, and customer support staff. All new hires receive extensive onboarding and field training to ensure consistent service standards.
In addition to technical growth, Carini Home Services plans to increase its community engagement. The company will sponsor local events, provide free educational workshops on home maintenance, and collaborate with neighborhood associations to promote energy efficiency and home safety. This outreach will strengthen the company’s relationship with the communities it serves and encourage proactive home care among residents.
As the service landscape evolves, Carini Home Services remains dedicated to staying ahead. Adding licensed electrical services ensures the company can meet the full range of residential needs with precision, safety, and transparency. Combined with its existing HVAC, water heater, and plumbing offerings, Carini Home Services is positioned as a comprehensive home services provider for San Diego County.
Homeowners in Del Mar, Chula Vista, Poway, Oceanside, La Mesa, and National City can schedule HVAC inspections, water heater replacements, plumbing repairs, and electrical upgrades through the company’s website. Flexible financing options and year-round discounts for seniors and military families back all services.
Carini Home Services operates out of its El Cajon headquarters and serves both residential and light commercial clients. For more information on newly available services or to request an estimate, visit www.carinihome.com or use the online scheduling portal.
NORTH PALM BEACH, FL / ACCESS Newswire / May 27, 2025 / The world of offshore sport fishing is a very close-knit community, and there are very few names that stir the sea quite like Taylor Jean. This Viking Convertible, which is 62 feet in length, is a unique and exceptional tournament yacht. It is sleek and powerful, and it is helmed by a crew that lives and breathes the wide sea. It is a story that is unfolding. From the 28th through the 31st of May 2025, it will once again be the center of attention at the 2nd Annual Walker’s Cay Blue Marlin Open, which is widely considered to be one of the most anticipated fishing competitions in the Bahamas.
A Yacht Built for Glory
Whenever Taylor Jean arrives at a marina, it is difficult to avoid staring at her. It is a beast that was built for speed and precision, as evidenced by its sleek lines, towering outriggers, and twin MTU motors that produce 2002 horsepower each. On the other hand, once you climb onboard, you will experience something else: a sense of purpose. Rather than being only a machine for sport fishing, this vessel serves as a floating home for a group of people who have become like family.
The current Taylor Jean, which first embarked in 2022, was designed with a single objective in mind, to strive for greatness. It is capable of performing with elegance and efficiency, whether it is traveling through the waters of the Bahamas at a speed of 36 knots or managing a hot bite on the tournament circuit.
The Crew Behind the Legend
What truly sets Taylor Jean apart isn’t just its speed, its engineering, or its tournament record, it’s the heartbeat of the boat, the people on board. Behind the polished teak, cutting-edge electronics, and twin MTU engines is a crew bound not just by a love for the ocean but by a shared spirit of competition, trust, and grit. Every line cast, every fish fought, every mile cruised, and it’s the crew that brings it to life.
Blaine Birch, a former collegiate lacrosse player with an unmistakable competitive edge, is currently serving as the captain of the crew. In every excursion, Blaine brings his keen instincts and his ability to lead with composure, guiding his group with self-assurance and a sense of togetherness.
Ken Hager, the owner, is also present, and he is not only the one who finances the dream. He is a living example. This crew is more than just a squad because it includes long-time teammates such as Dave McKendrick and Jarrett Birch (yep, Blaine’s brother). There’s a rhythm to this crew, one built on years of early mornings, high-stakes moments, and the kind of trust you can only earn at sea. They’ve celebrated wins, pushed through quiet days, and built a friendship that runs deeper than most tides. And tucked into their routine is a little superstition that’s become a legend among those who know them, before every tournament, someone scatters a handful of Lucky Charms into the water. No speeches. No ceremony. Just a quiet nod to tradition, a ritual that feels half superstition, half inside joke, and all heart. Maybe it’s luck. Perhaps it’s just who they are. Either way, it’s worked pretty well so far.
A Track Record That Speaks for Itself
Taylor Jean has been in the winner’s circle for quite some time. They finished in third place at the White Marlin Open in 2023, earning a total of 665 points. This is an impressive accomplishment in an event where the competition is just as fierce as the fish themselves. They then followed that up with an equally impressive performance in 2024, which resulted in them matching for third place in the Billfish release division with 770 points.
The yacht has also built a curious streak-claiming top finishes at The MidAtlantic every odd-numbered year since 2017. That kind of consistency speaks to more than just skill. It speaks to tenacity, preparation, and a team that knows how to rise when the stakes are highest.
What’s Coming: The 2025 Walker’s Cay Blue Marlin Open
Now, all eyes are on Walker’s Cay, which has been meticulously renovated and redesigned to become a crown jewel in the Bahamas. In addition to being famous for its deep-water drop-offs and legendary fishing, Walker’s is the ideal location for a Sportfishing Tournament that combines the excitement of competition with the sophistication of the past.
This is not your typical dockside competition, the Walker’s Cay SFC Blue Marlin Open is unlike any other. This event celebrates sport as much as it honors tradition, featuring a full sit-down Captain’s Dinner, an air-conditioned Awards Banquet, and spectacular ocean views.
Taylor Jean’s staff is already getting ready for the event, which includes adjusting the equipment, reviewing the charts, watching films from previous events, and, of course, making sure that the cereal boxes are stocked.
From High Stakes to High Seas: Charter Services with Taylor Jean
However, Taylor Jean is not only a dominant force in tournaments. In addition to that, it provides memorable charter fishing experiences for anyone interested in experiencing life at sea. It doesn’t matter if you’re looking for a day trip to go tuna fishing, a weekend vacation to go sailfish fishing, or just a chance to unplug with your loved ones and friends in opulent surroundings, the Taylor Jean experience will not disappoint.
By putting themselves in the same shoes that champion anglers have worn, guests are accompanied by seasoned anglers, supplied with the best equipment available, and cruise onboard one of the most luxurious yachts in its category. Every charter is customized to the guest’s level of experience if you are a dedicated offshore junkie or a first-timer to the underwater world.
The Legacy Continues
So, what is it about Taylor Jean that sets her apart? It may be the connection that exists between the members of the crew. It is the unwavering concentration. There is a possibility that it is the ideal combination of meticulous engineering and unbridled determination. It could be all of that and much more than that.
There is one thing that can be said with absolute certainty: on May 28th, Taylor Jean will once again be in its element, slashing through the blue of the Bahamas and running after another opportunity to make history.
Are they going to be successful in securing the big one at Walker’s Cay this year? If previous competitions are any indication, keep a close eye on this boat and consider bringing a box of Lucky Charms with you.
You can also catch full coverage and updates on the tournament at sportfishingchampionship.com, as well as through media like the Miami Herald, which regularly spotlights standout moments from the world of competitive sportfishing.
City, State: North Palm Beach, Florida Name: Kenneth Hager Company Name: Taylor Jean FL, LLC Email Address: ken@taylorjeanfishing.com Contact Number: (908) 433-6487 Website: taylorjeanfishing.com
